This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Array BioPharma Inc
ARRY : NASDAQ : Health Care
$4.04 | %
Today's Range: 3.98 - 4.05
Avg. Daily Volume: 2,082,000
11/27/15 - 12:59 PM ET

Financial Analysis

ARRAY BIOPHARMA INC's gross profit margin for the first quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth.

At the same time, stockholders' equity ("net worth") has greatly increased by 164.13% from the same quarter last year.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit

Income Statement Q1 FY16 Q1 FY15
Net Sales ($mil)16.26.07
EBITDA ($mil)0.0-24.22
EBIT ($mil)-18.37-25.1
Net Income ($mil)-20.99-27.59

Balance Sheet Q1 FY16 Q1 FY15
Cash & Equiv. ($mil)0.0110.7
Total Assets ($mil)186.75135.33
Total Debt ($mil)108.81105.26
Equity ($mil)24.1-37.58

Profitability Q1 FY16 Q1 FY15
Gross Profit Margin61.65-86.21
EBITDA Margin0.0-399.09
Operating Margin-113.42-413.53
Sales Turnover0.760.25
Return on Assets8.55-71.8
Return on Equity66.280.0
Debt Q1 FY16 Q1 FY15
Current Ratio0.02.17
Interest Expense2.662.51
Interest Coverage-6.92-10.0

Share Data Q1 FY16 Q1 FY15
Shares outstanding (mil)142.11131.83
Div / share0.00.0
Book value / share0.17-0.29
Institutional Own % n/a n/a
Avg Daily Volume2001613.01655325.0


SELL. ARRAY BIOPHARMA INC's P/E ratio indicates a significant premium compared to an average of 47.43 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 21.93. For additional comparison, its price-to-book ratio of 23.95 indicates a significant premium versus the S&P 500 average of 2.77 and a significant premium versus the industry average of 16.75. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, ARRAY BIOPHARMA INC proves to trade at a premium to investment alternatives within the industry.

1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
ARRY 58.00 Peers 47.43   ARRY NA Peers 42.69

Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.

ARRY is trading at a premium to its peers.


Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.

Ratio not available.

1 2 3 4 5
premium   discount
  Price to
1 2 3 4 5
premium   discount
ARRY NM Peers 19.59   ARRY NM Peers 0.56

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

ARRY's ratio is negative making this valuation measure meaningless.


Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

ARRY's negative PEG ratio makes this valuation measure meaningless.

1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
ARRY 23.95 Peers 16.75   ARRY 109.21 Peers 14.89

Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

ARRY is trading at a significant premium to its peers.


Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

ARRY is expected to have an earnings growth rate that significantly exceeds its peers.

1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
ARRY 4.06 Peers 289.74   ARRY 318.78 Peers 60.69

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

ARRY is trading at a significant discount to its industry on this measurement.


Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

ARRY has a sales growth rate that significantly exceeds its peers.



Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Real Money
Try it NOW

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums

Latest Stock Upgrades/Downgrades

Top Rated Stocks Top Rated Funds Top Rated ETFs